Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05121766 · ClinicalTrials.gov registry record · Phase 1
Feasibility Pilot Clinical Trial of Omega-3 Supplement vs. Placebo for Post Covid-19 Recovery Among Health Care Workers
A Phase 1 study, sponsored by Hackensack Meridian Health.
- Terminated
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT05121766 is a Phase 1 study that was terminated before completion, run by Hackensack Meridian Health. The registered enrollment target is 32 participants.
The verdict
NCT05121766, a Phase 1 study, was terminated before completion, sponsored by Hackensack Meridian Health.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a two-arm, double blind randomized 12-week study to supplement omega-3 (Eicosapentaenoic acid - EPA + docosahexaenoic acid - DHA) among 100 adults (age 18+) who had coronavirus-19 (covid-19) and are experiencing possible after-effects from post-acute sequelae of covid-19 (also called post-covid syndrome or long covid syndrome).
Interventions
- DRUG Placebo
- DRUG Omega-3 (EPA+DHA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-01-10 |
| Est. Completion | 2023-04-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05121766
The ClinicalTrials.gov registry entry for NCT05121766 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05121766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05121766 about?
NCT05121766 is a clinical study titled "Feasibility Pilot Clinical Trial of Omega-3 Supplement vs. Placebo for Post Covid-19 Recovery Among Health Care Workers". This is a two-arm, double blind randomized 12-week study to supplement omega-3 (Eicosapentaenoic acid - EPA + docosahexaenoic acid - DHA) among 100 adults (age 18+) who had coronavirus-19 (covid-19) and are experiencing possible after-effects from post-acute sequelae of covid-19 (also called post-co...
What is the current status of trial NCT05121766?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2022-01-10. Estimated completion is 2023-04-21.
What interventions are being tested in trial NCT05121766?
The interventions under investigation include: Placebo (DRUG), Omega-3 (EPA+DHA) (DRUG).
Who is sponsoring clinical trial NCT05121766?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.